Dow, S&P 500, Nasdaq futures slip amid Trump tariff fallout, with Iran-US talks on deck

☎️ RingCentral stock price near $40 in premarket after 34% jump

RingCentral stock hovered around $39.50 ahead of Monday’s open, holding close to where it finished on Friday.

The previous session saw shares surge 34.4%.

Moves like that can either extend or fade quickly once regular trading begins.

For RingCentral, the key question is whether buyers step back in as volume picks up.

The Belmont, California-based company reported on Feb. 19 that it generated $530 million in free cash flow for 2025, with guidance for 2026 set between $580 million and $600 million. TechStock² reports.


🛡️ CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares

CrowdStrike bounced 0.6% to $391 before the bell on Monday, making up just a fraction of Friday’s 7.95% drop.

Shares wrapped up last week at $388.60.

This shift is notable. Fresh concerns over AI disruption have already been driving investors away from expensive software stocks, with cybersecurity now getting caught up too.

It’s a critical moment for CrowdStrike, as the chatter lands just before its earnings. Any change in commentary on demand or the competitive landscape could quickly ripple through shares. TechStock² reports.


💊 Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti – what to watch at the open

Shares of Vanda Pharmaceuticals jumped roughly 33% to $7.68 in premarket trading Monday, following a late FDA approval announced Friday that triggered a surge after hours.

Early momentum has shifted attention to the rally’s staying power at the open.

Before the news broke after hours, the stock had dropped 5.5% during Friday’s regular session.

Investors are watching closely after the approval, as the company finally has a near-term commercial trigger in hand rather than waiting on distant trial data.

The key questions now are how quickly prescriptions materialize post-launch and whether the recent jump was partly driven by short covering. TechStock² reports.


💊 Novo Nordisk’s obesity drug CagriSema falls short against Eli Lilly’s in trial

Novo Nordisk said on Monday its next-generation obesity drug CagriSema was less effective than Eli Lilly’s tirzepatide in a head-to-head trial, a setback in the race for dominance in the weight-loss drug market.

The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but failed to meet that goal, Novo said in a statement.

The outcome is a blow to Novo Nordisk, which is fighting to regain its lost first-mover advantage in the lucrative obesity treatment market, where demand for drugs with higher efficacy is surging.

Novo Nordisk’s share price fell 13% by 1002 GMT. Yahoo Finance reports.


🍕 Domino’s Pizza earnings preview: what to expect from DPZ

Domino’s reports fiscal fourth-quarter 2025 results on February 23 before market open.

The quarter will test whether US same-store sales momentum from the second and third quarters carried through year-end, and whether the DoorDash aggregator rollout contributed meaningfully without eroding franchisee economics.

Consensus expectations sit at $5.38 EPS on $1.52 billion in revenue, representing 9.8% and 5.3% year-over-year growth, respectively.

Management has not issued formal quarterly guidance, leaving Wall Street to extrapolate from earlier commentary pointing to modest international growth and resilient US demand. AskTraders reports.


🤖 The AI boom is helping Samsung and coming for Apple

The global AI build-out has triggered a massive memory shortage that is expected to hit everything from smartphones to PCs.

For Korean tech giant Samsung, however, the AI era is proving to be a major payday.

The company’s stock recently hit an all-time high following reports that it is leveraging the chip shortage to aggressively raise prices on its next-generation HBM4 chips by up to 30%.

But in a twist of irony, Samsung could also end up feeling the sting of the shortage like every other tech company. Yahoo Finance reports.

*Estimate and Actual numbers represent Earnings Per Share in US Dollars


LINC: Lincoln Educational Servs
Q4 2025
Before Market Open
Estimate: 0.420
Actual: N/A

CNNE: Cannae Holdings
Q4 2025
After Market Close
Estimate: -0.370
Actual: N/A

BOOM: DMC Glb
Q4 2025
After Market Close
Estimate: -0.130
Actual: N/A

Time (ET) / Report / Period

8:00 AM - Fed governor Christopher Waller speaks - N/A
10:00 AM - Factory orders - Dec.

“Risk means more things can happen than will happen.”

– Elroy Dimson

Sourced in: Elroy Dimson on Risk – London Business School.

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.